Skip to main content
Caplight Logo









ThirtyFiveBio

ThirtyFiveBio

Private
AbingdonHealthcare & Life Scienceshttps://www.thirtyfivebio.com/

Last Round

VC Round

Apr 15, 2025

Total Funding Raised

$21.44M

Company Overview

ThirtyFiveBio is a biotechnology company developing first-in-class small-molecule inhibitors of G protein-coupled receptor 35 (GPR35) to treat severe gastrointestinal diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverysmall molecule inhibitorsGPR35 antagonistsulcerative colitisinflammatory bowel diseaseIBDgut epithelial shieldpreclinical researchbiotech startupgastroenterologytherapeutic developmentdrug pipelinebiotech R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ThirtyFiveBio Comparables

Compare ThirtyFiveBio with similar companies based on industry and business-model similarity.

ThirtyFiveBio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Nxera Pharma
73%
Bristol Myers Squibb
71%
N-Zyme Biomedical
70%

ThirtyFiveBio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundApr 15, 2025
GrantJul 2, 2024
GrantSep 13, 2023

ThirtyFiveBio Investors

Notable investors and investment history

ThirtyFiveBio investors
InvestorRounds
Innovate UKGrant
AbbVie VenturesVC Round
Innovate UKGrant
Canaan PartnersSeed, VC Round
Mayewell CapitalVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 15, 2025

    Raised $3.56M led by Canaan Partners

ThirtyFiveBio Filings

Explore SEC and related filing metadata, where available.

ThirtyFiveBio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about ThirtyFiveBio's valuation, stock price, and market status.

Is ThirtyFiveBio a public or private company?

ThirtyFiveBio is a private company.

What is the current stock price of ThirtyFiveBio?

ThirtyFiveBio is a private company with no public stock price. No recent secondary market data is available.

How much is ThirtyFiveBio worth (valuation)?

Valuation information for ThirtyFiveBio is not publicly available.

Can I buy ThirtyFiveBio stock?

ThirtyFiveBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was ThirtyFiveBio's last funding round?

ThirtyFiveBio's most recent funding round was VC Round on April 15, 2025.

Who are the main investors in ThirtyFiveBio?

Key investors in ThirtyFiveBio include Innovate UK, AbbVie Ventures, Canaan Partners, Mayewell Capital.

Will ThirtyFiveBio IPO soon?

No public IPO plans have been announced for ThirtyFiveBio.

How can I track ThirtyFiveBio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ThirtyFiveBio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersAbingdon
Employee Range12
Year Founded2021
Last FundingApr 15, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?